Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 12/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29035233 | 1.00 | SRC (0.46) | SRCMEN1KMT2ACYP1A2POLB | |
| SCHEMBL29035368 | 1.00 | SRC (0.46) | SRCMEN1KMT2ACYP1A2POLB | |
| SCHEMBL29523557 | 1.00 | SRC (0.46) | SRCMEN1KMT2ACYP1A2POLB | |
| SCHEMBL26565813 | 1.00 | SRC (0.46) | SRCMEN1KMT2ACYP1A2POLB | |
| SCHEMBL29523654 | 1.00 | SRC (0.46) | SRCMEN1KMT2ACYP1A2POLB | |
| SCHEMBL1828471 | 0.85 | SRC (0.50) | SRCMEN1KMT2ANR1H2TACR1 | |
| SCHEMBL4194648 | 0.85 | SRC (0.50) | SRCMEN1KMT2ANR1H2TACR1 | |
| SCHEMBL1828470 | 0.85 | SRC (0.50) | SRCMEN1KMT2ANR1H2TACR1 | |
| SCHEMBL29035297 | 0.85 | SRC (0.50) | SRCMEN1KMT2ANR1H2TACR1 | |
| SCHEMBL27228989 | 0.85 | SRC (0.50) | SRCMEN1KMT2ANR1H2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |